Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA-targeted CAR-T in advanced solid tumors
NCT07250386Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2025
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of C-13-60 in Advanced Malignant Solid Neoplasm (AMSN), non-small cell lung cancer (NSCLC) and breast cancer (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Safety of CAR-T cell preparations at 3 months and Recommended dose and infusion regimen at 3 months. Started Oct 2025; status: recruiting.
02
Drugs
C-13-60
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT07250386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250386.